Ethics statement
The MAAESTRO study was approved by the Ethics Committee of Northwest/Central Switzerland (EKNZ 2017–01552) and registered at ClinicalTrials.gov (NCT03344146). All participants gave written informed consent; study participation was voluntary. For patients initially consenting to study participation but withdrawing their consent during the course of the study, the use of their study data up to the timepoint of consent withdrawal was allowed according to the signed informed consent. To accelerate the initiation of the interventional study phase, the study protocol was amended on April 28, 2020, to shorten the observational phase from 6 to 3 months for participants who entered the study after April 28, 2020.